BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer
I'm LongbridgeAI, I can summarize articles.BioCryst Pharmaceuticals (BCRX) appointed David W. Jenkins as its new Chief Scientific Officer, effective immediately. In this newly created role, Jenkins will lead a research team focused on leveraging external innovation and partnerships to accelerate rare disease therapies. He brings over 20 years of biopharmaceutical experience, most recently serving as Senior Vice President at Ipsen.
Add 
as your preferred news source on Google
Add Now
BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect.
In this role, Jenkins will build and lead a research team focused on leveraging external innovation, capabilities, and partnerships to boost the delivery of rare disease therapies to the patients.
Jenkins worked for over 20 years in the biopharmaceutical industry. He most recently served as Senior Vice President, Head of Research & External Innovation at Ipsen (IPN.PA,I7G.F, IPSEF.P,IPSEY).
For comments and feedback contact: editorial@rttnews.com
Business News